Interpace Biosciences News Today

 ●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial...

Veracyte's products are marketed as LDTs and are not approved by the FDA. Click here to read more to know the reasons why VCYT stock has a Hold rating.

PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial...

NEW YORK, Sept. 7, 2022 /PRNewswire/ -- According to the latest report published by Growth Plus Reports, the global microRNA market is expected to clock US$ 846.33 million by 2030 and to grow

/PRNewswire/ -- Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma...

/PRNewswire/ -- Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma...

/PRNewswire/ -- DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the expansion of its...

The Business Research Company’s Biotechnology Services Global Market Report 2022 - Market Size, Trends, And Global Forecast 2022 - 2026

/PRNewswire/ -- The "Companion Diagnostics Development Services Market: Distribution by Type of Service Offered, Analytical Technique Used, Therapeutic Areas...

DUBLIN--(BUSINESS WIRE)--The "Companion Diagnostics Development Services Market: Distribution by Type of Service Offered, Analytical Technique Used, Therapeutic Areas and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.The "Companion Diagno...